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Consequences o f  Cytotoxic T Lymphocyte Interaction with 
Major Histocompatibi l ity Complex Class I-expressing 
Neurons In Vivo 
By Glenn E Rall, Lennart Mucke, and Michael B. A. Oldstone 
From The Scripps Research Institute, Division of Virology, Department of Neuropharmacology, 
La Jolla, California 92037 
Summary 
Neurons have evolved strategies to evade immune surveillance that include an inability to syn- 
thesize the heavy chain of the class I major histocompatibility complex (MHC), proteins that 
are necessary for cytotoxic T lymphocyte (CTL) recognition of target cells. Multiple viruses 
have taken advantage of the lack of CTL-mediated recognition and killing of neurons by estab- 
lishing persistent neuronal infections and thereby escaping attack by antiviral CTL. We have 
expressed a class I MHC molecule (D b) in neurons oftransgenic mice using the neuron-specific 
enolase (NSE) promoter to determine the pathogenic consequences of CTL recognition ofvi-  
rally infected, MHC-expressing central nervous system (CNS) neurons. The NSE-D b trans- 
gene was expressed in H-2 b founder mice, and transgene-derived messenger RNA was de- 
tected by reverse transcriptase-polymerase chain reaction in transgenic brains from several lines. 
Purified primary neurons from transgenic but not from nontransgenic mice adhered to cover- 
slips coated with a conformation-dependent monoclonal antibody directed against he D b mol- 
ecule and presented viral peptide to CTL in an MHC-restricted manner, indicating that the D b 
molecule was expressed on transgenic neurons in a functional form. Transgenic mice infected 
with the neurotropic lymphocytic horiomeningitis virus (LCMV) and given anti-LCMV, 
MHC-restricted CTL displayed a high morbidity and mortality when compared with controls 
receiving MHC-mismatched CTL or expressing alternative transgenes, After CTL transfer, 
transgenic brains showed an increased nutnber of CD8 + cells compared with nontransgenic 
controls as well as an increased rate of clearance of infectious virus from the CNS. Additionally, 
an increase in blood-brain barrier permeability was detected uring viral clearance in NSE-D b 
transgenic mice and lasted several months after clearance of virus from neurons. In contrast, 
LCMV-infected, nontransgenic littermates and mice expressing other gene products from the 
NSE promoter showed no CNS disease, no increased intraparenchymal CTL,  and no blood- 
brain barrier damage after the adoptive transfer of antiviral CTL. Our study indicates that viral 
infections and CTL-CNS interactions may induce blood-brain barrier disruptions and neuro- 
logic disease by a "hit-and-run" mechanism, triggering acascade of pathogenic events that pro- 
ceeds in the absence of continual viral stimulation. 
S everal properties unique to the central nervous system (CNS) 1 led to the concept hat the CNS is an immune- 
privileged site (1, 2). To recognize and lyse target cells 
within the brain parenchyma, immune effector cells must 
cross the blood-brain barrier, a tightly packed wall of en- 
dothelia that separates the circulatory system from CNS 
cells. While nutrients and oxygen either diffuse or are 
transported across the barrier, the passage of blood-borne 
Abbreviations u ed in this paper: aa, amino acid; CNS, central nervous sys- 
tem; LCMV, lymphocytic choriomeningitis v rus; mRNA, messenger 
1KNA; NP, nucleoprotein; NSE, neuron-specific enolase. 
proteins and cells (including red blood cells and resting 
lymphocytes) into the brain is restricted, because of both 
the fight junctions between the capillary endothelia nd a 
lack of active cell transport by the endothelial cells them- 
selves (for review see references 3 and 4). However, the 
barrier does not isolate the parenchyma from activated im- 
mune cells; activated T lymphocytes and monocyte/mac- 
rophages traverse the intact blood-brain barrier and traffic 
through the brain (5-9). These infiltrating, activated T cells 
are restricted from recognizing CNS targets, however, at 
least partly because of a paucity of cell surface molecules re- 
quired for T cell-target interaction. Resident cells of the 
CNS normally express low to undetectable vels of both 
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class I and II MHC molecules (10-12). The class I MHC 
glycoproteins present foreign (viral) proteins in the form of  
8-11 amino acid (aa) peptides to the T cell receptor of  
CD8 + cytotoxic T lymphocytes. Neurons, both in vivo 
(13-15) and in vitro (12, 14, 16-18), do not express MHC 
class I molecules and, hence, do not serve as targets for 
CTL-mediated lysis. Multiple RNA and DNA viruses, in- 
cluding members of the Herpes-, Paramyxo-, Rhabdo-, Pi- 
coma-, and Arenavirus families, infect neurons of the CNS 
(for review see references 19-21). Viruses from each of  
these families are able to establish latent or persistent infec- 
tions in CNS neurons, most likely because viral persistence 
in neurons through immune evasion is preferable to lysis by 
antiviral CTL of  these essential and irreplaceable cells. 
Earlier studies began to characterize neuron-v i rus-CTL 
interactions using the OBL-21 neuronal cell line (14). 
These cells contain neurofilaments and show electrophysi- 
ologic responses consistent with neurons (22), although, 
unlike CNS neurons, they are dividing cells. Like neurons 
in vivo, OBL-21 cells fail to express MHC molecules, and, 
although infected with virus and expressing viral proteins 
on their surfaces, were not lysed by antiviral CTL (14). 
However, after complementation f  class I MHC antigen- 
presenting capacity by transfection with a Db-encoding ret- 
roviral vector, infected OBL-21 cells were lysed by antivi- 
ral CTL (14). 
In this paper we extend these in vitro observations in 
vivo. First, transgenic mice that express a class I MHC mol-  
ecule on CNS neurons were established. Second, MHC-  
expressing neurons purified from such transgenic mice 
were susceptible to lysis by virus-specific MHC-restr icted 
CTL, whereas neurons from nontransgenic mice were not. 
CNS disease was induced in virally infected transgenic mice 
after adoptive transfer of virus-specific, MHC-restricted 
CTL. The disease lasted for several months after CTL 
transfer and was associated with an increased number o f in -  
traparenchymal CD8 + cells and a chronic destabilization f
the blood-brain barrier. 
Materials and Methods 
Animals, Cells, and Viruses. C57BL/6 (H-2b), SJL (H-29, and 
BALB/cByJ (H-2 a) inbred mice were obtained from the closed 
breeding facility of The Scripps Research Institute (La JoUa, CA). 
Animals were maintained in conditions consistent with American 
Association for the Accreditation of Laboratory Animal Care reg- 
ulations throughout the course of the investigation. 
Lymphocytic choriomeningitis virus (LCMV) strain Arm- 
strong CA 1371 clone 53b (LCMV ARM) was used in these 
studies. The origin, cloning and plaque purification of stock virus 
have been reported (23, 24). Virus was grown in baby hamster 
kidney cells and was plaque purified and titered on Vero cell 
monolayers as described (24). BALB clone 7 (H-2 a) fibroblasts 
and Vero cells were grown in MEM supplemented with 10% 
heat-inactivated FCS, 1 mM r-glutamine, 104 U/ml penicillin, 
and 10 mg/ml streptomycin. MC57 (H-2 b) fibroblasts were cul- 
tured in RPMI 1640 with the supplements listed above. CTL 
clones restricted by H-2 b (clone NP18 recognizing nucleoprotein 
[NP] aa residues 396-404; 25) and H-2 a (clone HD8 recognizing 
NP aa residues 118-127; 26) were used. These clones were main- 
rained in culture as described (25). 
Persistent infection of mice was achieved by inoculation of 
1,000 PFU of LCMV ARM intracerebrally into newborn mice 
within 18 h of birth. Such mice carry infectious virus and viral 
nucleic acid in many cells, including neurons, throughout their 
lives (27). 
Cloning Procedures and Establishment of Transgenic Mice. Stan- 
dard molecular techniques (28, 29) were used for the construc- 
tion of the NSE-D b transgene. The NSE expression vector (30, 
31) was obtained from S. Forss-Petter, (The Scripps Research In- 
stitute) and the Mo/D b clone (32) from R. Flavell, (Yale Univer- 
sity, New Haven, CT). Promoter-transgene junctions created by 
the subcloning were sequenced before microinjection. Fertilized 
oocytes were obtained from (C57B1/6 • SJL) female mice. Puri- 
fication of the transgene, preparation ofmice, microinjection, and 
embryo implantations were carried out as described (33-35). 
Transgenic mice were identified by tail biopsy and subsequent 
DNA isolation. 10 FLg of DNA was slot blotted onto filters (Ny- 
tran; Schleicher & Schuell, Inc., Keene, NH) and probed with 
the SV40 sequence located at the 3' end of the NSE expression 
cassette. 
Reverse Transcriptase-PCR ( T-PCR). Brains and other or- 
gans were removed from saline-perfused mice and were snap fro- 
zen in liquid nitrogen. The tissues were stored at -70~ before 
homogenization. Tissues were homogenized using a Virtishear 
(Virtis Co., Inc., Gardiner, NY) for 30 s in 1 ml Tri-reagent/100 
mg tissue (Molecular Research Center, Inc., Cincinnati, OH), 
and RNA was purified according to their recommended proto- 
col. 500 ng of total RNA was reverse transcribed by the random 
priming method, using random hexamers (Pharmacia Biotech, 
Inc., Piscataway, NJ) and reverse transcriptase (GIBCO BRL, 
Gaithersburg, MD). The RNA-cDNA duplex was then sub- 
jected to 40 rounds of PCR (60~ annealing temperature; Taq I 
polymerase from GIBCO BRL), using 20-mer oligonucleotide 
primers designed to amplify transgene specific sequences: A = 5' 
GAGAT CGACT CTAGA GGATC 3'; B = 5' GCGCT 
CTGGT TGTAG TAGCC 3'. The PCR products were visual- 
ized by ethidium bromide intercalation on a 1% agarose gel. 
Hippocampal Neuron Cultures and Protein Detection. Embryonic 
mice (day 16-18) were used for the preparation of dissociated 
hippocampal neuron cultures following the protocol of Banker 
and Goslin (36) with minor modifications (37; Rall, G. F., un- 
published results). Briefly, hippocampi were dissected from em- 
bryos and placed in ice-cold plating medium (DMEM supple- 
mented with 10% fetal bovine serum, 104 U/ml penicillin, and 10 
mg/ml streptomycin). The tissues were washed three times with 
ice-cold PBS and digested with trypsin-EDTA (Sigma Chemical 
Co., St. Louis, MO) at 37~ for 15 rain. The tissue was washed 
twice with plating medium, mechanically dissociated with fire- 
polished pipettes, and passed through a cell strainer (Falcon Lab- 
ware, Oxnard, CA) to obtain a single-cell suspension. The neurons 
were spun at 150 g for 7 rain onto a serum cushion, resuspended, 
counted, and plated onto either poly-L-lysine (Sigma Chemical 
Co.) or antibody-coated, acid-washed, round glass coverslips 
(Carolina Biological Supply Co., Burlington, NC) at a density of 
500 cells/mm 2.
Individual coverslips were incubated with affinity-purified goat 
anti-mouse IgG (Cappel Laboratories, Cochranville, PA; 10 p~g/ 
slip) for 4 h, washed with PBS and then coated with rnAbs spe- 
cific for either the D b class I MHC molecule (B22. 249.R1, 1:500; 
Cedarlane Laboratories Ltd., Homby, Ontario, Canada) or to the 
L a class I MHC molecule (30-5-7S, 1:500; Cedarlane Laborato- 
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ries Ltd.) in doses of 3 Fg/coverslip (38, 39). Coverslips were 
placed in a humidified incubator overnight, and, immediately be- 
fore neuron plating, the antibody was aspirated and the slips were 
washed once with PBS, pH 7.4. 
4 h after the neurons were added to the coverslips, the slips 
were placed on top of a confluent primary astrocyte feeder layer 
(40), in serum-free neurobasal medium (GIBCO BRL) supple- 
mented with growth factors (B27 additive; GIBCO BRL). The 
cells were maintained at37~ in 5% CO2. 
In Vitro Killing Assay. Neurons cultured in vitro for 48 h 
were either untreated or were coated with peptides representing 
LCMV CTL epitopes restricted by either H-2 b (NP aa 396-404: 
NH2-FQPQNGQFI -COOH) or H-2 d (NP aa 118-127: NH2- 
SERPQASGVG-COOH) at a concentration of 40 beg/2 • 104 
targets 1 h before the addition of CTL. H-2 b- or H-2a-restricted 
CTL clones were then added to the cultures at a 1:1 ratio, and 
they were allowed to incubate for 6 h. After removal of the 
clones and debris by successive PBS washes, the neurons were 
fixed with 2% paraformaldehyde and were counterstained with 
hematoxylin. 10 random fields were counted per slide, and the 
results were confirmed in three independent experiments. MC57 
(H-2 b) and BALB c17 (H-2 a) fibroblasts served as controls. 
Adoptive Transfer of Memory CTL into Persistently Infected 
Mice. Adoptive transfer of antiviral CTL into persistently in- 
fected mice has been described (41). The memory cytotoxic ef- 
fector cells transferred were obtained from normal adult C57BI/6 
or SJL mice infected 60-120 d earlier by intraperitoneal inocula- 
tion of 2 X 10 s PFU of LCMV. Spleens were removed and disso- 
ciated, and a single-cell suspension was prepared and cultured in 
24-well plates with syngeneic LCMV-infected and irradiated 
peritoneal macrophages (as stimulators) and syngeneic irradiated 
spleen ceils (as feeder cells). Adherent lymphocytes (secondaries) 
were expanded three times on infected, irradiated stimulator cells 
before transfer into age-matched (6-13-wk-old) persistently in- 
fected mice and nontransgenic controls. 
Transgenic and nontransgenic mice (H-2 b) were bred with 
nontransgenic SJL mice (H-2 s) to generate H-2 bxs mice for the 
adoptive transfer experiments. The progeny of such breedings 
was infected with LCMV (103 PFU) within 24 h of birth to es- 
tablish persistent infections. The presence of virus in these mice 
(between 4 and 8 wk) was determined before the adoptive trans- 
fer by serum plaque assay. 24 h before the transfer of 5 X 106 sec- 
ondary CTL intraperitoneally, mice were irradiated with 400 rad 
to accommodate he adoptively transferred cells. The health of 
the animals was monitored aily from 1 to 30 d after adoptive 
transfer and weekly thereafter, and evaluated on a four-level scale: 
1, healthy and indistinguishable from uninfected normal mice; 2, 
fur slightly ruffled, posture hunched, eyes partially closed, re- 
duced mobility; 3, ruffled, hunched, and tremulous, eyes mucous 
filled and closed, significant motor impairment; 4, dead. 
Viral titers in serum were monitored 6, 15, 60, and 120 d after 
adoptive transfer, and mice from experimental nd control groups 
were killed at 15 and 60 d after adoptive transfer for histological 
studies. 
Detection of CD8 + Lymphocytes within Brain Sections. /Mice were 
deeply anesthetized with a 3.8% solution of chloral hydrate and 
were perfused with normal saline. Brains were rapidly removed, 
quick frozen in a dry ice/isopentane bath, and stored at -70~ 
10-1am horizontal sections were cut and fixed in 95% ethanol for 
15 min at -20~ were blocked with avidin-biotin (Vector Lab- 
oratories, Inc., Burlingame, CA), and were incubated for 1.5 h 
with mAbs to the murine CD8 molecule (CD8a and Ly3, diluted 
1:50; Pharmingen, San Diego, CA). After washing, sections were 
incubated with biotinylated secondary antibodies, followed by an 
avidin-biotin reaction (ABC Elite; Vector Laboratories, Inc.) and 
a color reaction using diaminobenzidene and hydrogen peroxide. 
Sections were lightly counterstained with hematoxylin and were 
mounted with Aquamount (Lemer Laboratories, New Haven, CT). 
The median values of the number of CD8 + lymphocytes per 
brain section within a given group were calculated. At least four 
horizontal sections were evaluated per mouse brain. 
Blood-Brain Barrier Permeability. Mice were deeply anesthe- 
tized with a 3.8% solution of chloral hydrate. 2 ml of a 2% Evans 
blue solution in PBS was infused transcardially over a l-rain pe- 
riod. 3 rain later, mice were perfused with 4% paraformaldehyde 
in PBS, and brains were removed and stored in 0.2% paraformal- 
dehyde in PBS. 
Results 
The Class I MHC Molecule, D ~, Is Expressed in Neurons of 
Transgenic Mice. Transgenic mice with neuronal  expres- 
sion of  the class I MHC molecule D b were established by 
injection of  oocytes with a minigene containing the com-  
plete D b coding sequence under  the control of  the NSE 
promoter  (Fig. 1). The D b minigene (40) was cloned into 
the BamHI  restriction site within exon 2 of  the NSE cas- 
sette (Fig. 1), and the resulting plasmid was characterized 
by restriction analysis and sequencing of  promoter- t rans-  
gene junctions. The linearized, gel-purified NSE-D b trans- 
gene was then microinjected into ~200 (C57B1/6 • SJL)F2 
one-cel l  stage embryos. 
From this microinjection, 42 mice were born, 12 of  
which contained the transgene. Five of  these founder mice 
were selected for breeding and were back-crossed onto the 
C57B1/6 background. After three back-crosses, the CTL  
response within these mice was completely restricted to the 
H-2  b haplotype as determined by chromium release assays 
(data not  shown). 
Tissue expression of  the NSE-D b messenger RNA 
(mRNA)  was analyzed by RT-PCR on RNA isolated 
from transgenic and nontransgenic mouse tissues (brain, 
el e2 .,~1 
I 5' REGULATORY SEQ~.CE ~ ~  NSE CASSETTE 
l k b ~  poly A~ ' 
I ' ,t o b MIN,QENE 
el I1 e2 i2 e 3-8 3' UTR 
500 bp 
Figure 1. Structure of the NSE-D b fusion gene. The NSE-D b con- 
struct consists of 2.8 kb ofS' NSE regulatory sequence, NSE exon 1 and 
intron 1, and 15 bp ofNSE exon 2 plus polylinker. The D b minigene in- 
cludes all 8 exons and the first two introns of the murine D b gene. Poly- 
adenylation signals are provided by 3' untranslated sequences (UTR) of 
the D b minigene. SV40 sequence at the 3' end of the construct facilitates 
identification of transgenic mice by slot blot analysis ofgenomic DNA. e, 
exon; i, intron. 
1203 Rall et al. 
Figure 2. Expression fD b mRNA in brains oftransgenic mice. Brains 
were removed from transgenic (+) and nontransgenic (-) mice. Total 
RNA was extracted and subjected toRT-PCR as described in Materials 
and Methods, Primers A and B were used to amplify transgene-specific 
mRNA. The primer pair was designed to differentiate spliced and un- 
spliced templates by size; the primers pan intron 1 of the D b sequence, so
that the predicted PCR product derived from spliced mRNA is 180 bp 
smaller than the product derived from either unspliced RNA or residual 
DNA in the preparation (Fig. 2 13). Spliced mRNA (as a 320-bp PCR 
product) was detected in each of the five transgenic l nes, and, in some 
cases, aPCR product corresponding to DNA or unspliced RNA (500 bp) 
was seen (lines 23 and 29). No PCR product was amphfied in nontrans- 
genic mice (line 21-). Results obtained in three mice per group are 
shown. 
spleen, kidney, pancreas, liver, testes, gut, thymus, lung, 
heart, and optic and sciatic nerves). Total brain RNA iso- 
lated from mice of  six transgenic lines (7, 9, 11, 21, 23, and 
29) contained transgene-derived mRNA,  whereas brain 
RNA from nontransgenic littermates did not (Fig. 2 A). 
Transgenic lines 9 (data not shown) and 11 were used for 
subsequent experiments. No spliced NSE-D b mRNA was 
detected in other organs except for in the testes of  line 29 
(data not shown). Line 29 was not used for further experi- 
ments. 
Total RNA purified from primary astrocyte/microglial 
cultures derived from transgenic neonatal mice of lines 9 
and 11 were also analyzed by the RT-PCR approach. No 
RNA PCR product corresponding to the NSE-D b trans- 
gene was detected in these cultures (data not shown). 
The NSE-D b expression at the protein level was too low 
to be detected by immunostaining of tissue sections. How-  
ever, neuronal expression of D b protein was demonstrated 
by culturing primary embryonic hippocampal neurons and 
testing their ability to grow on glass coverslips coated with 
an mAb specific for either D b or for a heterologous MHC 
molecule (anti-Ld). Neurons from transgenic (Db-express- 
ing) mice adhered to anti-D b-, but not to anti-L&coated 
coverslips (Fig. 3). Nontransgenic neurons did not attach 
to either type of  coverslip, confirming the absence of  
MHC class I on their surface. Notably, the antibody used, 
B.22.249, is conformation dependent (32). Therefore, the 
D b molecule is expressed in a conformationally correct 
form on the surface oftransgenic neurons. 
The Transgene-derived D b Molecule Conferred CTL  Rec- 
ognition and Lysability to CNS Neurons In Vitro. We next de- 
termined whether transgenic neurons could present antigen 
and serve as targets for CTL-mediated lysis in a neuronal 
survival assay. Primary neurons do not take up S~Cr; there- 
fore, instead of  standard chromium release assays, an alter- 
native assay was used. Transgenic and nontransgenic neu- 
rons were incubated with peptides encoding LCMV-specific 
epitopes that are restricted by either H-2 b or H-2 d (25, 26, 
35). Peptide-coated neurons were reacted with specific 
anti-LCMV H-2 b- or H-2&restricted CTL clones, and the 
number of  viable neurons was determined after a 6-h incu- 
bation. Db-expressing eurons incubated with H-2 b- 
restricted viral peptide and a matched CTL clone showed a 
significant reduction (73%) in cell viability (P < 0.05), 
whereas nontransgenic neurons did not (Fig. 4). These data 
were reproducible in three independent experiments. 
Persistently Infected, Transgenic Mice Developed CNS Disease 
after Adoptive Transfer of LCMV-specific Db-restricted CTL. 
NSE-Db-expressing mice were maintained in a specific 
pathogen-free facility. No differences in appearance, fecun- 
dity, or life span were noted between uninfected transgenic 
animals and nontransgenic littermate controls (data not 
shown). 
To determine the antigen-presenting capacity of  trans- 
genic neurons in vivo and the consequences of their inter- 
action with Db-restricted CTL, mice were infected as neo- 
nates with LCMV. In this persistent infection, most tissues, 
including the CNS, liver, spleen, and kidney, contain 
LCMV; within the CNS, the neuron is the only cell type 
infected (42, 43). Adoptive transfer of  virus-specific, 
MHC-restricted CTL (41, 44) results in CTL-mediated 
clearance of LCMV from all sites, other than neurons and 
renal glomeruli, within 10-30 d after transfer. The eventual 
elimination of  virus and viral nucleic acid from neurons oc- 
curs over a longer period (60-120 d after adoptive transfer) 
and does not involve obvious infiltration of  the brain pa- 
renchyma (41). The mechanism of viral clearance from 
nontransgenic, persistently infected brains is not completely 
understood, but does not seem to occur via classical CTL -  
target cell interactions. 
NSE-D b transgenic mice, NSE-amyloid precursor pro- 
tein (APP) transgenic mice (expressing APP as a non-MHC 
transgenic ontrol; 31), and nontransgenic littermates were 
infected with LCMV at birth. Each of these groups of  mice 
was generated by breeding an H-2 b transgenic parent with 
a nontransgenic SJL (H-29 mouse, resulting in H-2 bX~ off- 
spring. Secondary immune T lymphocytes raised in H-2 b 
or H-2 ~ mice were then adoptively transferred into the per- 
sistently infected H-2 bx~ animals. This experiment was based 
on the following rationale: both H-2 b and H-2 ~ anti- 
LCMV CTL could recognize virally infected cells in pe- 
ripheral tissues of  persistently infected H-2 bx~ mice, but 
only H-2 b anti-LCMV CTL would recognize viral antigen 
complexed with the D b molecule on NSE-D b transgenic 
neurons. Thus, if mice became sick or died as a conse- 
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Figure 3. Expression ofD b molecules on the surface of neurons i olated from the CNS of transgenic mice. Primary embryonic hippocampal neurons 
from transgenic and nontransgenic litters were plated onto c verslips coated with mAbs to either D b (B22.249) or L a (30-5-7S) as described inMaterials 
and Methods. Photographs were taken 48 h after plating. Staining with antibody against the neuronal marker, microtubule-associated protein 2 indicated 
that >95% of the adherent cells were neurons. 
quence of  CTL interactions with the D b expressed on neu- 
rons, this should be seen only in NSE-D b transgenic mice 
receiving the H-2b-restricted CTL (Fig. 5). 
Animal health was monitored daily and independently 
by at least two investigators after adoptive transfer of  CTL. 
The genetic profile of  the mice and the CTL that they re- 
ceived were unknown to the observers to avoid bias. Per- 
sistently infected mice appeared healthy before the adoptive 
transfer. 5-15 d after transfer, when CTL are killing virally 
infected MHC-expressing cells in peripheral tissues (liver, 
spleen, kidney, etc.) (41), some mice showed mild to mod- 
erate illness (clinical levels 2-3) in all experimental groups. 
The combined results (Table 1) of  three independent adop- 
tive transfer xperiments using a minimum of  four mice per 
experimental group revealed the following: (a) NSE-D b 
transgenic mice exposed to H-2 b CTL showed significantly 
higher morbidity and mortality than NSE-APP or non- 
transgenic ontrols receiving similar immunotherapy; (b) 
NSE-D b mice had a higher morbidity and mortality when 
given H-2 b CTL compared with H-2 + CTL, whereas H-2 b 
and H-2 s CTL had a similar effect in the control groups; 
and (c) NSE-D b mice that survived the initial 15-d viral 
clearance period remained sick throughout the observation 
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period (clinical stages 2-3), whereas control mice returned 
to clinical stage 1 after viral clearance. 
NSE-lY' Transgenic Mice Receiving Adoptive CTL Therapy 
Showed Increased Numbers of CD8 + Lymphocytes in the CNS 
Parenchyma and Accelerated Viral Clearance. Brains were re- 
moved from mice at various time points after adoptive trans- 
fer and stained with mAbs to murine CD8 to compare the 
number of infiltrating CTL within the brains of  NSE-D b 
transgenic versus control mice. Photomicrographs of  repre- 
sentative routine brains are shown in Fig. 6, and a quantita- 
tive summary is shown in Table 2. Uninfected NSE-D b 
transgenic brains contained rare CTL (Fig. 6 A; Table 2, 
group A), suggesting that the expression of  D b on neurons 
per se is not sufficient to recruit T cells into the paren- 
chyma. The CD8 § CTL found within the brains of  persis- 
tently infected mice were distributed uniformly throughout 
the parenchyma, and both transgenic and nontransgenic 
mice killed at various ages after neonatal LCMV infection 
contained similar numbers of  intraparenchymal CD8 § T 
cells (Fig. 6 B; Table 2, groups B and C). In contrast, 15 d 
after adoptive transfer of  Db-restricted anti-LCMV CTL, 
there was a marked increase in the number of  CD8 + T 
cells within brains of  persistently infected, NSE-D b trans- 
Figure 4. Lysis of Db-expressing primary neurons coated with appro- 
priate viral peptide by Db-restricted LCMV-specific CTL. Primary neu- 
rons were incubated for 1 h with peptides encoding epitopes f r LCMV 
restricted by either H-2 b (viral NP, aa 396-404) or H-2 d (NP, aa 118- 
127) or with no peptide (- -). One hour after peptide addition, H-2 b- or 
H-2a-restricted antiviral CTL were added to the cultures. 5-6 h later, 
neurons were fixed, stained, and counted as described in Materials and 
Methods. Numbers of neurons in cultures incubated with no peptide and 
H-2 d CTL were arbitrarily defined as 100%. Data points represent th  
number of remaining neurons expressed a  a percentage of this control; 
error bars indicate SD. Similar results were obtained independently i  two 
additional experiments (data not shown). * P values <0.05 by the Stu- 
dent's t test, 
genic mice (Fig. 6 C; Table 2, group D), which was not 
seen in nontransgenic ontrols receiving similar immuno-  
therapy (Fig. 6 D; Table 2, group E). Interestingly, in areas 
densely populated with LCMV- in fec ted  neurons, such as 
the hippocampus and the Purkinje cell layer o f  the cerebel- 
lum, no obvious signs of  neuronal dropout were seen, sug- 
gesting that infected neurons were not lysed by CTL.  By 
day 40, the number  o f  CTL  in the brains o f  transgenic 
Figure 5. Rationale of the adoptive transfer protocol. See text for de- 
scription. 
mice had decreased (Fig. 6 E; Table 2, group F). Similar 
findings were obtained in at least three mice per experi-  
mental group. 
Brain tissues taken from mice 15 and 40 d after adoptive 
transfer were also plaque assayed to assess the effect o f  the 
neuronal MHC expression on the clearance o f  virus f rom 
transgenic brains. Whi le  virus was still present in brains o f  
nontransgenic control mice 15 d after adoptive transfer, v i -  
rus was no longer detectable at this t ime point  in transgenic 
brains receiving the H-2  b secondary lymphocytes (Fig. 7). 
Notably,  despite an accelerated viral clearance, transgenic 
mice remained sick for up to 120 d after the adoptive trans- 
fer. 
The Increased Sickness of NSE-D b Transgenic Mice Correlated 
with a Chronic Disruption ~ the Blood-Brain Barrier. To  de- 
termine whether  the increased number  o f  CTL  in the CNS 
Table  1. Occurrence of Sickness and Death in NSE-D a, NSE-APP, and Nontransgenic Persistently Infected Mice 
Receiving H-2 ~ or H-2~restricted Antiviral CTL* 
Injury after adoptive transfer in days (in %) 
Day 5-15 Day 15-60 Day 60-120 
CTL 
Transgene Mice MHC Sickness Death Sickness Death Sickness Death 
n 
NSE-D b, line 9 18 H-2 b 100 33 85 0 69 0 
NSE-D b, line 9 8 H-2 ~ 50 12 14 0 0 I) 
NSE-D b, line 11 14 H-2 b 93 43 78 0 88 0 
NSE-D b, line 11 10 H-2 ~ 25 0 11 0 11 0 
NSE-APP and 52 H-2 b 40 8 4 0 10 6 
Nontransgenic 15 H-2 ~ 47 7 12 0 14 0 
* 5 • 106 CTL were transferred into persistently infected H-2 TM NSE-D t', NSE-APP, or nontransgenic mice. Health was monitored aily, and ac- 
cumulated sickness and death measurements are presented as the percentage ofthe total number of animals in each group. 
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Figure 6. Increased number of CD8 + cells in brains of  transgenic, persistently infected mice after adoptive transfer of  H-2b-restricted anti-LCMV 
CTL. Sections ofcaudate (A-D) or cerebellum (E) were stained for the presence ofCD8 § lymphocytes a described in Materials and Methods, and were 
counterstained with hematoxylin. (A) Uninfected NSE-D b transgenic mouse, no CTL given; (B) persistently infected NSE-D b mouse, no CTL given; 
(C) persistently infected, NSE-D b transgenic mouse, day 15 after adoptive transfer of  H-2 b secondaries; (D) persistently infected, nontransgenic mouse, 
day 15 after adoptive transfer of  H-2 b secondaries; (E) persistently infected, NSE-D b transgenic mouse, day 40 after adoptive transfer of H-2 b secondaries. 
• 100. 
o i 
~0 
3 
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DAY 0 DAY 15 DAY 40 
Figure 7. Clearance of  infectious virus from brains of  transgenic and 
control mice. Brains of  persistently infected NSE-D b or control (non- 
transgenic or NSE-APP) mice were removed 15 or 40 d after adoptive 
transfer of H-2 b CTL, weighed, homogenized, and analyzed for the pres- 
ence of infectious virus by plaque assay. At least four animals per group 
were evaluated. Results represent means + SD. 
Figure 8. Abnormal permeability of the blood-brain barrier in persis- 
tently infected NSE-D b mice after adoptive transfer of H-2 b LCMV-spe- 
cific CTL. Persistently infected mice were injected with Evans blue and 
peffused as described in Materials and Methods. (A) Nontransgenic 
mouse, no CTL given; (B) persistently infected NSE-D b transgenic 
mouse given H-2' antiviral CTL 120 d previously; (C) persistently in- 
fected, nontransgenic mouse given H-2 b CTL and showing signs of  sick- 
ness after 15 d after transfer; (D and E) persistently infected NSE-D b mice 
given H-2 b CTL 120 d previously. 
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would be associated with an alteration of the blood-brain 
barrier, mice were injected with Evans blue, a dye which 
binds to serum proteins and is excluded from the brain pa- 
renchyma by the normal blood-brain barrier. In persis- 
tently infected NSE-D b transgenic mice, leakage of the dye 
into the brain parenchyma was observed as early as 15 d 
(n = 4) (data not shown) and as late as 120 d (n = 5) after 
adoptive transfer of H-2 b restricted CTL (Fig. 8; Table 3). 
These results indicate a prolonged abnormal permeability 
of the blood-brain barrier, which persisted in the absence 
of viral antigen. Subtle differences in the pattern of perme- 
ability changes could be related to variations in the distri- 
bution or activity of the infiltrating lymphocytes. 
By contrast, no other group of mice, including tran- 
siently sick nontransgenic mice killed 9 d after CTL admin- 
istration, showed any abnormality in the permeability of 
the blood-brain barrier (Table 3; Fig. 8). 
Discussion 
The current study revealed a number of novel findings. 
The expression of class I MHC glycoproteins in neurons of 
NSE-D b transgenic mice had no deleterious effects on the 
health, fecundity, or life span of uninfected mice. MHC 
class [-expressing hippocampal neurons of transgenic mice 
presented exogenous viral peptide to H-2-matched CTL 
in vitro, resulting in neuronal lysis. In vivo interactions of 
antiviral H-2b-restricted CTL with Db-expressing neurons 
in mice persistently infected with LCMV resulted in signif- 
icant morbidity and mortality. Disease induced in the trans- 
genic mice was associated with an increase in the number 
of CD8 § T lymphocytes within the brain parenchyma, n 
increased rate of clearance of infectious virus from infected 
neurons, and an increased permeability of the blood-brain 
barrier that continued for several months after the adoptive 
transfer of CTL and after the virus was cleared from in- 
fected neurons. Although virus was cleared from Db-expres- 
sing neurons by 15 d after adoptive transfer, no obvious ly- 
sis of neuronal cells was observed. 
Our in vitro findings in transgenic primary embryonic 
neurons confirm and extend previous results obtained in 
OBL-21 neuronal cells (14, 17). In those studies it was 
shown that OBL-21 cells were unable to present viral anti- 
gen to CTL because of a paucity of class I MHC on the 
OBL-21 cell surface. Molecular complementation with a 
retrovirally expressed class I MHC molecule made infected 
OBL-21 cells recognizable and lysable by antiviral CTL. 
Although OBL-21 cells share many characteristics with 
neuronal cells (e.g., expression ofneurofilaments, NSE, and 
voltage-dependent potassium channels; 22), they, unlike 
primary neurons, are dividing, transformed cells that grow 
in the presence of serum. 
Expressing Db MHC class I proteins in neuronal cells via 
transgenic technology and panning with mAb to D b in the 
current study allowed the in vitro analysis of primary neu- 
ronal cell-virus-CTL interactions. As these primary neu- 
rons do not divide in culture and are grown in the absence 
of serum, they resemble differentiated neurons in the intact 
CNS more closely than OBL-21 cells. When transgenic 
Db-expressing primary neurons were pulsed with viral pep- 
tide or infected with virus (Rail, G., and M. B. A. Old- 
stone, unpublished results) and challenged with MHC-  
matched antiviral CTL, they were recognized and lysed, 
whereas primary neurons from nontransgenic mice under 
similar conditions were not. Thus, expression of a class I 
MHC molecule on primary neurons in vitro was sufficient 
to result in lysis by appropriate CTL. 
Interestingly, we did not find evidence of CTL-medi- 
ated lysis of neurons in brains of transgenic mice, despite 
the presence of intraparenchymal CTL and rapid viral 
clearance from the transgenic CNS. However, it should be 
noted that this study was not designed to accurately quanti- 
tate neuronal counts and that a subtle dropout of neurons 
may have occurred. Nevertheless, neurons of the hippo- 
campus and Purkinje cell layer of the cerebellum are uni- 
formly infected by LCMV in vivo (41, 42); yet at no time 
after adoptive transfer, in no animal, regardless of health, 
were morphological changes consistent with cell lysis ob- 
served in these regions. Thus, while transgenic neurons ex- 
pressing the correct viral peptide bound to a transgenic 
MHC molecule were suitable CTL targets in vitro, such 
neurons did not appear to be effectively lysed in vivo. This 
observation may be due to a restricted number of CD8 § 
CTL within the brain, which limits the cytotoxic effect of 
these cells. We believe this possibility is unlikely, however, 
given the rapid rate of viral clearance and blood-brain bar- 
rier damage within transgenic brains. 
Alternatively, one might consider that, while these neu- 
rons express the transgene in vitro, they may not in vivo, as 
no direct evidence (e.g., immunohistochemical identifica- 
tion of the transgene product in brain sections) is provided. 
We feel that our inability to detect he class l molecule in 
brain sections was due to technical problems regarding the 
difficulty of immunostaining within the brain, coupled 
with the lack of a suitable, high-affinity antibody, and not 
due to the absence of expression in vivo. The adoptive 
transfer experiments provide strong evidence for functional 
protein expression i  vivo: three groups of mice (NSE-D b, 
NSE-APP, and nontransgenic littermates), two lines of the 
NSE-D b mice (lines 9 and 11), and two different immune 
lymphocyte haplotypes (b and s) were used to demonstrate 
a selective ffect of H-2 b antiviral ymphocytes on virally 
infected H-2 b transgenic neuronal targets. Because only the 
combination of mice expressing the D b molecule with 
MHC-matched H-2 b immune lymphocytes resulted in 
pathological conditions (increased intraparenchymal CTL, 
increased blood-brain barrier permeability, prolonged sick- 
ness), functional expression of the class I MHC transgene in 
neurons is the most plausible xplanation for these data. 
How these CTL exert their virucidal, but not cytocidal, 
effects in vivo is not known. It is conceivable that factors 
released from neurons or glial cells interfere with lytic 
CTL-neuronal interactions contributing to the relatively 
immunosuppressive/immune-privileged microenvironment 
of the CNS, and that such factors interfere with the CTL- 
mediated cytolysis of vitally infected neurons. Isolation of 
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Table 2. Accumulation ofCD8 + T Cells Present in Brains of Mice Receiving Adoptive Transfer of Immune Lymphocytes* 
Median number of 
intraparenchymal 
Adoptive transfer of CD8 + T cells$ 
H-2 b anti-LCMV CTL 
Group Mice Virus Transgene (day observed) Median Range 
n 
A 3 - + - 12 (0-17) 
B 4 + - - 48 (19-82) 
C 4 + + - 55 (14-89) 
D 5 + + + (15) 124 (48-211) 
E 4 + - + (15) 62 (23-77) 
F 4 + + + (40) 51 (15-69) 
*Persistendy infected (groups B-F) or uninfected (group A) NSE=D btransgenic (groups A, C, D, and F) or nontrausgenic (groups B and E) mice 
were given either H-2b-restricted antiviral CTL (groups D-F) or no CTL (groups A-C). Brains were examined immunohistochemically for the 
presence ofCD8 + T cells at either 15 (groups D and E) or 40 (group F) d after transfer as described inMaterials and Methods. 
*Values given represent the median umber of CD8 § positive cells found/horizontal brain section (determined from four sections per mouse, 
three-five mice per group). 
Table 3. Increase in Transgenic Mouse Blood-Brain Barrier Permeability Is Dictated by Expression of the Transgene 
in Virally Infected Mice Given Haplotype-matched Antiviral CTL* 
Experimental model Result 
Neurons expressing in vivo 
MHC class I LCMV 
Adoptive transfer 
of Db-restricted, 
LCMV= specific CTL 
Percent incident of 
increased blood-brain 
barrier permeability 
+ + + 100 (5/5) 
+ - - o (0 /5 )  
+ - + 0 (0/3) 
+ + - 0 (0/4) 
- + + o (0 /5 )  
- + - 0 (0 /5 )  
*Persistently infected (+) or uninfected (-) NSE-D b transgenic (+) or nontransgenic (-) mice were given Db-restricted antiviral CTL 120 d before 
blood-brain barrier assessment. Permeability was determined by entry of Evans blue into the parenchyma. The percentages of mice with Evans blue 
infiltration are given, with the total number of mice per group in parentheses. 
neurons from this environment by in vitro culture may re- 
move them from these factors and allow lysis to occur. 
Expression of a functional MHC molecule on neurons 
also induced a protracted isruption of the blood-brain 
barrier. This effect may be mediated by soluble CTL prod- 
ucts such as cytokines. Since the effector cells in the adop- 
tive splenocyte transfer have been shown to be virus-spe- 
cific CD8 + (41), the most likely cytokines would be IFN-~/ 
and TNF-oL. Studies to directly test this hypothesis are cur- 
rently underway using IFN-'y and TNF-oe knockout mice. 
Cytokines have recently been shown to cause direct injury 
within the CNS in which injection (45) or endogenous 
synthesis (46) of cytokines resulted in several clinical and 
histopathologic changes within the brain, including blood- 
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brain barrier damage. 
After adoptive transfer of MHC-restricted virus-specific 
CTL into mice whose neurons contain virus but lack 
expression of MHC class I molecules, clearance occurs by 
60-120 d (41). Interestingly, in the model reported here, 
clearance occurs much earlier, by day 15 (Fig. 7). In both 
instances, clearance of virus from neurons occurs in the 
absence oflysis of these cells, suggesting that intraparenchy- 
real cytokine production may also participate in the clear- 
ance of infectious virus from transgenic brains. Inhibition 
of viral synthesis in the absence of cell death has been doc- 
umented in the CTL response to hepatitis B virus infection 
of hepatocytes (47-49) and in HIV (50). In these systems, 
inflammatory cytokines such as IFN-~/ and TNF-ci can 
down-regulate viral expression without concomitant cell 
death. 
The stability of  the blood-brain barrier is critical to the 
exclusion of potentially neurotoxic or cytolytic blood- 
borne molecules (such as cytokines) from the CNS paren- 
chyma as well as to the maintenance of  an appropriate ho- 
meostatic osmotic balance within the brain (51). Whi le 
rapid alterations in the permeability of  the blood-brain bar- 
rier may result in edema and death (52, 53), slower changes 
in permeability need not be life threatening but may lead to 
more chronic neurologic symptoms (54). In agreement 
with this concept, we observed a significant increase in an- 
imal sickness and death at early times after adoptive trans- 
fer, with continued sickness of  surviving mice throughout 
the 150-d observation period. 
Several CNS diseases have been associated with transient 
or permanent changes in blood-brain barrier permeability, 
including those associated with CNS infection (54-58), de- 
myelinating diseases (59), and tumors (60). Our study, in 
which abnormal permeability of  the blood-brain barrier 
and clinical illness were detected long after virus had been 
cleared from the mice (Fig. 7), indicates that viral infections 
and CTL-CNS interactions may induce blood-brain bar- 
rier disruptions and neurologic disease by a "hit-and-run" 
mechanism, triggering a cascade of  pathogenic events that 
proceeds in the absence of  continual viral stimulation. 
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